Galcanezumab
- Generic Name
- Galcanezumab
- Brand Names
- Emgality
- Drug Type
- Biotech
- CAS Number
- 1578199-75-3
- Unique Ingredient Identifier
- 55KHL3P693
- Background
Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities with high potency. Given this target specificity, lack of off-target toxicity, and characteristic proteolysis profile of immunoglobulin antibodies to not undergo metabolism by liver enzymes, galcanezumab possesses favourable and promising safety and tolerability. Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache. It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.
- Indication
Galcanezumab is indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
- Associated Conditions
- Episodic Cluster Headache, Migraine
The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Albany Medical College
- Target Recruit Count
- 25
- Registration Number
- NCT06901518
- Locations
- 🇺🇸
Albany Medical Center, Albany, New York, United States
Migraine Medication Effects on Urinary Symptoms
- Conditions
- Bladder Pain SyndromeMigraine DisordersMigraineOveractive BladderOveractive Bladder SyndromeOveractive DetrusorInterstitial Cystitis
- Interventions
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT06212661
- Locations
- 🇺🇸
Cleveland Clinic, Main Campus, Cleveland, Ohio, United States
Emgality for Migraine in Breastmilk
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2025-04-07
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT06085144
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Diamond Headache Clinic
- Target Recruit Count
- 2
- Registration Number
- NCT05492695
- Locations
- 🇺🇸
Diamond Headache Clinic, Chicago, Illinois, United States
Real World Effectiveness of Eptinezumab in Participants With Migraine
- Conditions
- Migraine
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 32
- Registration Number
- NCT05284019
- Locations
- 🇺🇸
Gilbert Neurology Partners/ CCT Research, Gilbert, Arizona, United States
🇺🇸Ki Clinical Research LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸Innovation Medical Group, Palmetto Bay, Florida, United States
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
- Conditions
- MigraineMigraine With AuraMigraine Without AuraChronic MigraineEpisodic Migraine
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Austrian Migraine Registry Collaboration
- Target Recruit Count
- 1500
- Registration Number
- NCT05281770
- Locations
- 🇦🇹
Medical University Innsbruck, Innsbruck, Tirol, Austria
🇦🇹Clinic Hietzing, Vienna, Austria
🇦🇹Medizinische Universität Wien, Wien, Vienna, Austria
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
- Conditions
- MigraineEpisodic Migraine
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 580
- Registration Number
- NCT05127486
- Locations
- 🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸Gilbert Neurology, Gilbert, Arizona, United States
🇺🇸California Medical Clinic for Headache and The Los Angeles Headache Center (Research Facility), Los Angeles, California, United States
Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly
- Conditions
- Migraine
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Campus Bio-Medico University
- Target Recruit Count
- 300
- Registration Number
- NCT04803513
- Locations
- 🇮🇹
Campus Bio Medico University Hospital, Rome, RM, Italy
CGRP Inhibition, Autonomic Function, and Migraine
- Conditions
- Episodic MigraineChronic Migraine
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 120
- Registration Number
- NCT04628429
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT04616326
- Locations
- 🇺🇸
Rehabilitation & Neurological Services, Huntsville, Alabama, United States
🇺🇸21st Century Neurology, a Division of Xenoscience, Inc., Phoenix, Arizona, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.